FTC’s Misguided Pharma Policy Harms Public Health

Most of the focus on government policy during the COVID-19 pandemic has focused on the various steps—and often missteps—of the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA). Yet behind the scenes lurks another governmental actor that may have an ever-larger influence over pharmaceutical development in the United States: The Federal Trade Commission (FTC), which regulates competitive practices and oversees merger activity.